Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

Triple Negative ◽

Line Treatment ◽

First Line ◽

Limited Efficacy ◽

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.01.065 ◽

2021 ◽

Author(s):

A. Brufsky ◽

S.B. Kim ◽

Ž. Zvirbule ◽

A. Eniu ◽

J. Mebis ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Primary Analysis ◽

SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz100.047 ◽

2019 ◽

Vol 30 ◽

pp. iii63

Author(s):

V. Boni ◽

C. Alemany ◽

J.L. Meisel ◽

R. Sinha ◽

D. Sterrenberg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Open Label Phase ◽

OT3-01-08: Phase II Study of S-1 Combined with Cisplatin in the First-Line Treatment of Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-08 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)

10.1158/1538-7445.sabcs19-ot2-08-02 ◽

2020 ◽

Cited By ~ 1

Author(s):

Peter Schmid ◽

Javier Cortes ◽

Mark Robson ◽

Hiroji Iwata ◽

Roberto Hegg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs19-pd1-06 ◽

2020 ◽

Cited By ~ 2

Author(s):

Hyo (Heather) Han ◽

Sami Diab ◽

Carlos Alemany ◽

Reva Basho ◽

Ursa Brown-Glaberman ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase 1B ◽

IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps1104 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1104-TPS1104 ◽

Cited By ~ 8

Author(s):

Leisha A. Emens ◽

Sylvia Adams ◽

Sherene Loi ◽

Andreas Schneeweiss ◽

Hope S. Rugo ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Triple Negative ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

UPDATE SURVIVAL OF PHASE 1B CLINICAL TRIAL OF HX008, A NOVEL ANTI-PD-1 MONOCLONAL ANTIBODY, COMBINED WITH GEMCITABINE AND CISPLATIN IN THE FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER

The Breast ◽

10.1016/s0960-9776(21)00545-2 ◽

2021 ◽

Vol 59 ◽

pp. S48

Author(s):

Jun Cao ◽

Xichun Hu ◽

Biyun Wang ◽

Jian Zhang ◽

Leiping Wang ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Monoclonal Antibody ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Phase 1B ◽

First Line Treatment ◽

Gemcitabine And Cisplatin

tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps1146 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS1146-TPS1146 ◽

Cited By ~ 1

Author(s):

Denise A. Yardley ◽

Adam Brufsky ◽

Robert E. Coleman ◽

Pier Franco Conte ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps1100 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1100-TPS1100 ◽

Cited By ~ 1

Author(s):

David Miles ◽

Sung-Bae Kim ◽

V. A. McNally ◽

Brian P. Simmons ◽

Matthew Wongchenko ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Safety And Efficacy ◽

Phase 2 Study ◽

TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz242.076 ◽

2019 ◽

Vol 30 ◽

pp. v138

Author(s):

A.H. Awada ◽

J. Cortés ◽

S. Slater ◽

I. Macpherson ◽

T. Csoszi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Locally Recurrent ◽